证券代码：300119 证券简称：瑞普生物 3、请问原料药板块上半年经营情况？ 编号：2025-004 | | 特定对象调研 分析师会议 □ √ | | --- | --- | | 投资者关系活动 | 媒体采访 业绩说明会 □ □ | | | 新闻发布会 路演活动 □ √ | | 类别 | □ 现场参观 | | | □ 其他 | | | 国泰海通证券、中金公司、高盛香港、长江证券、中信证券、中 | | | 信建投证券、西南证券、华创证券、浙商证券、天风证券、广发 | | | 证券、华泰证券、国海证券、申万宏源证券、华福证券、国联民 | | | 生证券、华安证券、光大证券、银河证券、兴业证券、华鑫证券、 | | | 东兴证券、西部证券、开源证券、财通证券、首创证券、万和证 | | | 券 | | | 博道基金、财通基金、德邦基金、广发基金、九泰基金、泉果基 | | | 金、新疆前海联合基金、华泰保兴基金、国融基金、西部利得基 | | 参与单位名称 | 金、广东正圆私募基金、荷荷晴川私募、上海睿胜私募基金、苏 | | （63 家） | 州高新私募基金、深圳安通私募基金、WT China Fund Limited、 ...

金十数据6月9日讯，瑞普生物在互动平台上表示，超比欣已于今年5月上市，妙普净计划近期上市。 瑞普生物：妙普净计划近期上市 ...

Financial Performance - In Q1 2025, the company achieved a revenue of 8.22 billion yuan, representing a year-on-year growth of 20% [3] - The net profit attributable to shareholders was 1.16 billion yuan, with a year-on-year increase of 28.45% [3] - The non-recurring net profit reached 9.35 million yuan, showing a growth of 19.65% year-on-year [3] Business Strategy - The company is focusing on international brand strategy, marking its transition from a regional to a global brand [3] - A 56% stake acquisition in Zhongrui Supply Chain was completed, enhancing collaboration across core business segments [3] - The company is implementing a share repurchase plan, with a total repurchase amount of 120 million yuan as of March 31, 2025 [3] Product Development - The high pathogenic avian influenza vaccine generated 87 million yuan in revenue, a 16% increase year-on-year, while the Marek's vaccine revenue reached 26 million yuan, up 59% [4] - The company plans to launch new products, including a cat oral dewormer and various mRNA vaccines for pets, to enrich its product matrix [4][5] Market Expansion - The company has nearly 100% coverage of its top 100 customers in the traditional livestock sector and aims to deepen strategic cooperation with major clients [6][7] - The international strategy includes a dual circulation approach for product and technology, focusing on overseas market expansion and enhancing service capabilities [7] Impact of Tariffs - Export business accounts for approximately 3% of total revenue, indicating minimal direct impact from US-China tariffs [7] - The company is monitoring tariff policy changes to adjust its business layout and product strategies accordingly [7]